NMRA — Neumora Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1885522 ·
Last close
$1.53
Market Cap
$283.48M
52W High
$2.82
52W Low
$0.83
ADV30
2,745,484
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -52,864,000 | -53,458,000 | 153,877,000 | 147,072,000 | 83,197,000 |
| Dec 2025 | 0 | — | -58,480,000 | -59,450,000 | 191,047,000 | 182,530,000 | 87,176,000 |
| Sep 2025 | 0 | — | -57,700,000 | -56,755,000 | 177,833,000 | 129,071,000 | 45,672,000 |
| Jun 2025 | 0 | — | -54,040,000 | -52,731,000 | 223,825,000 | 124,523,000 | 40,946,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-206,440,000
Investing CF
$168,520,000
Financing CF
$77,089,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.45
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,184,149,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-238,398,000
Pretax Income TTM
$-236,798,000
Interest Exp TTM
$2,783,000
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -241,156,000 | -236,928,000 | 191,047,000 | 87,176,000 | — | -206,440,000 |
| Dec 2024 | 0 | -263,464,000 | -243,787,000 | 316,972,000 | 29,908,000 | — | -182,936,000 |
| Dec 2023 | 0 | -252,098,000 | -235,925,000 | 496,195,000 | 27,119,000 | — | -163,278,000 |
| Dec 2022 | 0 | -135,870,000 | -130,904,000 | 426,234,000 | 873,084,000 | — | -114,896,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.79
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $1.53 · call volume: 1,230 · put volume: 19Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SRZN | Surrozen, Inc./DE | $279.11M | $24.04 | — |
| IVVD | Invivyd, Inc. | $274.34M | $0.93 | — |
| SABS | SAB Biotherapeutics, Inc. | $295.15M | $3.86 | — |
| PALI | PALISADE BIO, INC. | $305.50M | $1.76 | — |
| HUMA | Humacyte, Inc. | $261.25M | $0.97 | — |
News headlines (Yahoo Finance, 1h cache)
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data
2026-06-17 15:17 · Yahoo
Three pivotal MDD trial failures for Neumora lead to staffing cuts
2026-06-16 15:58 · Yahoo
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
2026-06-16 14:13 · Yahoo
Neumora depression drug fails; EnGene to cut 50% of staff
2026-06-16 09:08 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-06-15 19:46 · Yahoo
Sector Update: Healthcare Stocks Softer Monday Afternoon
2026-06-15 17:50 · Yahoo
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
2026-06-15 17:21 · Yahoo
Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA)
2026-06-15 13:28 · Yahoo
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
2026-06-15 12:00 · Yahoo
SoftBank Just Dumped Circle Stock. Don’t Panic and Keep Adding CRCL Here.
2026-05-19 19:49 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.